Megestrol acetate
Highest phase reached
Approved
Drug type
Small molecule
First approval year
1971
- First approval year
- 1971
- Listing at source
- Listed
- Highest phase reached
- Approved
- Drug type
- Small molecule
- Drug name
- Megestrol acetate
- Molecular weight
- 384.52
- Structure (SMILES)
- CC(=O)O[C@]1(C(C)=O)CC[C@H]2[C@@H]3C=C(C)C4=CC(=O)CC[C@]4(C)[C@H]3CC[C@@]21C
- megace
- Megace
- megace es
- Megace es
- megestrol acetate
- Megestrol acetate
- 17 hydroxy 6 methylpregna 4 6 diene 3 20 dione acetate
- 17-Hydroxy-6-methylpregna-4,6-diene-3,20-dione acetate
- 5071
- 6 methyl 3 20 dioxopregna 4 6 dien 17 yl acetate who ip
- 6-METHYL-3,20-DIOXOPREGNA-4,6-DIEN-17-YL ACETATE [WHO-IP]
- apetrol es megace
- bdh 1298
- BDH 1298
- BDH-1298
- chronopil
- Chronopil
- MEDROXYPROGESTERONE ACETATE IMPURITY G [EP IMPURITY]
- MEDROXYPROGESTERONE ACETATE IMPURITY G [WHO-IP]
- medroxyprogesterone acetate impurity g ep impurity
- medroxyprogesterone acetate impurity g who ip
- megace
- Megace
- megesterol acetate
- Megesterol acetate
- megestrol
- Megestrol
- megestrol 17 alpha acetate
- Megestrol 17.alpha.-acetate
- megestrol acetate
- Megestrol acetate
And 46 more, listed on the interactive page.
- CAS registry numbers
- 595-33-5
- ChEMBL ID
- CHEMBL1201139
- InChIKey
- RQZAXGRLVPAYTJ-GQFGMJRRSA-N
- PubChem compound IDs
- 11683
- FDA ingredient codes (UNII)
- TJ2M0FR8ES
- G03AC05
- G03DB02
- L02AB01
Sources for recorded values
- 6703
- 29451
- Applicant
- BRISTOL MYERS SQUIBB
- Approval date
- 18 Aug 1971
- Application number
- NDA016979
- Patents
- 0
- Designations
- 1
- First in class
- No
- Fast track
- No
- Breakthrough designation
- No
- Orphan designation
- No
- Priority review
- No
- Orphan exclusivity
- No
- Accelerated approval
- No
- Availability
- Prescription only
- United States (FDA)
- Approved
- Drug name stem
- -estr-; -gest-
Administration routes
- Oral
Mechanisms of action
- Mechanism
- Progesterone receptor agonist
- Action type
- Agonist
- Target
- Progesterone receptor
- Protein identifier
- P06401
Open Targets mechanisms
- Mechanism
- Progesterone receptor agonist
- Action type
- Agonist
- Target
- Progesterone receptor
DrugCentral mechanisms
- Action type
- Agonist
- Gene symbol
- PGR
- Protein identifier
- P06401
- Organism
- Homo sapiens
- Target development level
- Clinical
- Condition
- Pulmonary Disease, Chronic Obstructive
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000341
- Subject identifier
- D029424
- Condition
- Neoplasms
- Highest recorded phase
- 4
- Condition identifier
- EFO:0000616
- Subject identifier
- D009369
- Condition
- Acquired Immunodeficiency Syndrome
- Highest recorded phase
- 4
- Condition identifier
- EFO:0000765
- Subject identifier
- D000163
- Condition
- Breast Neoplasms
- Highest recorded phase
- 3
- Condition identifier
- EFO:0003869
- Subject identifier
- D001943
- Condition
- Endometrial Neoplasms
- Highest recorded phase
- 3
- Condition identifier
- EFO:0004230
- Subject identifier
- D016889
- Condition
- Head and Neck Neoplasms
- Highest recorded phase
- 2
- Condition identifier
- EFO:0006859
- Subject identifier
- D006258
- Condition
- HIV Wasting Syndrome
- Highest recorded phase
- 2
- Condition identifier
- EFO:0007312
- Subject identifier
- D019247
- Condition
- Endometrial Neoplasms
- Highest recorded phase
- 3
- Condition identifier
- EFO:0007532
- Subject identifier
- D016889
- Condition
- Adrenal Cortex Neoplasms
- Highest recorded phase
- 2
- Condition identifier
- EFO:1000796
- Subject identifier
- D000306
- Condition
- Endometrial Neoplasms
- Highest recorded phase
- 3
- Condition identifier
- EFO:1001512
- Subject identifier
- D016889
- Condition
- Dementia
- Highest recorded phase
- 2
- Condition identifier
- HP:0000726
- Subject identifier
- D003704
- Condition
- Anorexia
- Highest recorded phase
- 4
- Condition identifier
- HP:0002039
- Subject identifier
- D000855
- Condition
- Cachexia
- Highest recorded phase
- 4
- Condition identifier
- HP:0004326
- Subject identifier
- D002100
- Condition
- Hot Flashes
- Highest recorded phase
- 3
- Condition identifier
- HP:0031217
- Subject identifier
- D019584
- Condition
- Liver Neoplasms
- Highest recorded phase
- 3
- Condition identifier
- MONDO:0002691
- Subject identifier
- D008113
- Condition
- Uterine Neoplasms
- Highest recorded phase
- 2
- Condition identifier
- MONDO:0002715
- Subject identifier
- D014594
- Condition
- Primary Immunodeficiency Diseases
- Highest recorded phase
- 4
- Condition identifier
- MONDO:0003778
- Subject identifier
- D000081207
- Condition
- Neoplasms
- Highest recorded phase
- 4
- Condition identifier
- MONDO:0004992
- Subject identifier
- D009369
- Condition
- Breast Neoplasms
- Highest recorded phase
- 3
- Condition identifier
- MONDO:0007254
- Subject identifier
- D001943
- Condition
- Endometrial Neoplasms
- Highest recorded phase
- 3
- Condition identifier
- MONDO:0011962
- Subject identifier
- D016889
- Condition
- Carcinoma in Situ
- Highest recorded phase
- 2
- Condition identifier
- MONDO:0024474
- Subject identifier
- D002278
- Condition identifier
- EFO_0000341
- Highest recorded phase
- 2
- Condition identifier
- EFO_0000616
- Condition identifier
- EFO_0000764
- Highest recorded phase
- 3
- Condition identifier
- EFO_0000765
- Condition identifier
- EFO_0003060
- Highest recorded phase
- 3
- Condition identifier
- EFO_0004230
- Condition identifier
- EFO_0006859
- Highest recorded phase
- 3
- Condition identifier
- EFO_0007312
- Highest recorded phase
- 2
- Condition identifier
- EFO_0008572
- Highest recorded phase
- 3
- Condition identifier
- EFO_1000098
- Condition identifier
- EFO_1000235
- Highest recorded phase
- 2
- Condition identifier
- EFO_1001271
- Highest recorded phase
- 3
- Condition identifier
- EFO_1001512
- Highest recorded phase
- 2
- Condition identifier
- EFO_1001514
- Highest recorded phase
- 1
- Condition identifier
- HP_0000846
- Condition identifier
- HP_0001508
- Condition identifier
- HP_0001824
- Highest recorded phase
- 3
- Condition identifier
- HP_0002039
- Condition identifier
- HP_0002039
- Highest recorded phase
- 4
- Condition identifier
- HP_0004326
- Condition identifier
- HP_0004326
- Highest recorded phase
- 4
- Condition identifier
- HP_0030016
- Highest recorded phase
- 3
- Condition identifier
- HP_0031217
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0001627
- Condition identifier
- MONDO_0001627
- Highest recorded phase
- 2
And 29 more, listed on the interactive page.
- Event
- abasia
- Reports
- 8
- Reporting signal score
- 10.0433
- Event
- addison's disease
- Reports
- 5
- Reporting signal score
- 18.6822
- Event
- adrenal insufficiency
- Reports
- 49
- Reporting signal score
- 168.81
- Event
- adrenal suppression
- Reports
- 4
- Reporting signal score
- 13.1953
- Event
- androgen deficiency
- Reports
- 5
- Reporting signal score
- 24.1936
- Event
- asthenia
- Reports
- 33
- Reporting signal score
- 9.8565
- Event
- blood chloride decreased
- Reports
- 9
- Reporting signal score
- 26.4238
- Event
- blood cortisol decreased
- Reports
- 7
- Reporting signal score
- 28.033
- Event
- blood glucose increased
- Reports
- 18
- Reporting signal score
- 15.5701
- Event
- blood testosterone decreased
- Reports
- 8
- Reporting signal score
- 22.1206
- Event
- blood urea increased
- Reports
- 10
- Reporting signal score
- 14.5168
- Event
- breast cancer
- Reports
- 13
- Reporting signal score
- 15.6482
- Event
- breast cancer metastatic
- Reports
- 14
- Reporting signal score
- 40.291
- Event
- carbohydrate antigen 15-3 increased
- Reports
- 4
- Reporting signal score
- 15.5362
- Event
- cognitive disorder
- Reports
- 11
- Reporting signal score
- 10.5609
- Event
- decreased appetite
- Reports
- 24
- Reporting signal score
- 11.9261
- Event
- deep vein thrombosis
- Reports
- 113
- Reporting signal score
- 280.888
- Event
- dementia alzheimer's type
- Reports
- 98
- Reporting signal score
- 510.404
- Event
- failure to thrive
- Reports
- 10
- Reporting signal score
- 27.4786
- Event
- haematocrit
- Reports
- 3
- Reporting signal score
- 18.0732
- Event
- hypogonadism
- Reports
- 5
- Reporting signal score
- 16.6613
- Event
- hypomagnesaemia
- Reports
- 9
- Reporting signal score
- 12.9995
- Event
- intracranial pressure increased
- Reports
- 6
- Reporting signal score
- 13.0971
- Event
- invasive lobular breast carcinoma
- Reports
- 5
- Reporting signal score
- 20.5318
- Event
- listless
- Reports
- 7
- Reporting signal score
- 21.4448
And 17 more, listed on the interactive page.
- NCT00001079
- NCT00002067
- NCT00006799
- NCT00031707
- NCT00031785
- NCT00163072
- NCT03283488
- NCT01200602
- NCT01501396
- NCT05380479
- NCT00002680
- NCT01237327
- NCT02269670
- NCT03306472
- NCT00005975
- NCT00016341
- NCT00739830
- NCT00910091
- NCT05255653
- NCT05332483
- NCT00041275
- NCT00070148
- NCT00420563
- NCT00503516
- NCT00503581
And 12 more, listed on the interactive page.
- Dose
- 800mg
- Route
- Oral
- How often
- Once daily
Conditions of use
- Shake well before using
- Hydrogen bond acceptors
- 4
- Hydrogen bond donors
- 0
- Polar surface area
- 60.44
- Calculated partition coefficient (ALogP)
- 4.58
- Calculated partition coefficient (XLogP)
- 3.1
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Rule-of-five violations
- 0
- Rotatable bonds
- 2
- Heavy atoms
- 28
- Molecular formula
- C24H32O4
- Monoisotopic mass
- 384.23005950
- Natural product
- Yes
- 0116-4011
- 0121-0945
- 0121-1038
- 0555-0606
- 0555-0607
- 0904-7236
- 0904-7577
- 24979-041
- 51407-910
- 60687-916
- 64380-158
- 64380-159
- 64380-160
- 68094-063
- 68094-174
- 69339-160
- 70954-896
- 71205-943
- 81033-150
- 17856-0060
- 68788-8714
- 71335-2181
- 71335-2544
- Recorded assays
- 3,527
- Active assays
- 175
- Confirmatory
- Other
- Screening
- Summary
- Antineoplastic Agents, Hormonal
- Appetite Stimulants
These details could not be displayed.
Related records
Trials (102)
- A Clinical Study of Nanocrystalline Megestrol Acetate in Concurrent Chemoradiotherapy for Locally Advanced Cervical Cancer
- A Clinical Trial to Evaluate Pharmacokinetics of Daewon DW-ES(A) 625mg/5ml, Daewon DW-ES(B) 625mg/5ml and Megace 800mg/20ml in Healthy Male Volunteers Under Fed Condition
- A Phase I/II Study to Evaluate Single Agent and Combination Therapy With Megestrol Acetate and Dronabinol for the Treatment of HIV-Wasting Syndrome
- A Phase II Study of Therapy With Paclitaxel, Carboplatin and Megesterol Acetate for the Management of Uterine Cancer
- A Pilot Study on Fertility Conservative Treatment of Atypical Endometrial Hyperplasia in Singapore
- A Pre-operative Window Study of Letrozole Plus PR Agonist (Megestrol Acetate) Versus Letrozole Alone in Post-menopausal Patients With ER-positive Breast Cancer
- A Preliminary Exploratory Study of Cadonilimab Combined With Progestin for Fertility-Sparing Treatment in Early Endometrial Cancer
- A Prospective Real-World Observational Study of Nanocrystalline Megestrol Acetate in Patients With Cancer Cachexia
- A Randomized Clinical Trial of Megestrol Acetate as an Appetite Stimulant in Malnourished Children With Cancer
- A Study Comparing Megestrol Acetate at 800 mg/Day, and Placebo in AIDS Patients With Anorexia and Cachexia
- A Study Evaluating Megestrol Acetate Modulation in Hormone Receptor Positive Advanced Breast Cancer
- A Study of Different Doses of Megestrol Acetate in Patients With AIDS Who Have Anorexia and Malnutrition
- A Study of Megestrol Acetate Alone or in Combination With Testosterone Enanthate Drug in the Treatment of HIV-Associated Weight Loss
- A Study of Megestrol Acetate in HIV-Infected Children
- A Study of MK-5684 in People With Certain Solid Tumors (MK-5684-015/OMAHA-015)
- A Study on Nausea and Vomiting Caused by T-DXd in Breast Cancer Patients
- Adrenal Suppression and Adrenal Recovery Induced by Megestrol Acetate
- Clinical Study on Nanocrystalline Megestrol Acetate for Appetite Improvement and Weight Gain in Pre-Cachexia and Cachexia Stages Key Terminology Analysis
- Clinical Trial of Rapid Progressive Central Precocious Puberty With Integrative Chinese and Western Medicine
- Clinical Trial of Ridaforolimus Compared to Progestin or Chemotherapy for Advanced Endometrial Carcinoma (MK-8669-007 AM6)
Approved for (4)
In development for (25)
- Adrenal cortex carcinoma Phase 2
- Atypical endometrial hyperplasia Phase 2
- Breast cancer Phase 3
- Breast neoplasm Phase 3
- Cervical cancer Phase 1
- Chronic obstructive pulmonary disease Phase 2
- Dementia Phase 2
- Endometrial cancer Phase 3
- Endometrial carcinoma Phase 3
- Endometrioid adenocarcinoma Phase 2
- Endometrium adenocarcinoma Phase 2
- Endometrium neoplasm Phase 3
- Gastric adenocarcinoma Phase 2
- Head and neck cancer Phase 2
- Head and neck squamous cell carcinoma Phase 3
- Hepatocellular carcinoma Phase 3
- HIV infectious disease Phase 2
- HIV wasting syndrome Phase 2
- Intraepithelial neoplasia Phase 2
- Liver cancer Phase 3
Other linked conditions (3)
Targets (1)
- PGR Progesterone receptor agonist